BioClinica Responds to Shareholder Letter
-Board Supports Management-
NEWTOWN, Pa.--(BUSINESS WIRE)--Sep 30, 2010 - BioClinica™, Inc. (NASDAQ: BIOC), a global provider of clinical trial management services, has issued the following statement:
The Board of Directors of BioClinica supports management, their extensive industry-specific knowledge, insight and business acumen. The Company has a strategic plan in place to enhance shareholder value, and we are executing upon that plan to build our business and strengthen and expand our suite of services while increasing our operational efficiency. We also have substantial and growing interest in our new eClinical offerings.
Management has always been open to discussions with our shareholders, and it is our intent to continue that dialogue in an effort to facilitate an understanding of our Company, its operations and our strategic growth plan. We are in receipt of a letter from one of our shareholders who has published that letter in the form of a press release. We want to assure our shareholders that the Company remains focused on enhancing long-term shareholder value and delivering high quality clinical trial services to our clients.
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.
Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.
Contact: BioClinica, Inc.
Ted Kaminer, 267-757-3000
Chief Financial Officer
Porter, LeVay & Rose, Inc.
Investors: Linda Decker
Financial Media: Bill Gordon
Posted: September 2010
Recommended for you